r209130
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
145 Active assets in the Schizophrenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
Asenapine Noven Pharmaceuticals, Inc. | Phase 4 | BBB |
Xanomeline European Group for Research In Schizophrenia | Phase 4 | BBB |
TROSPIUM European Group for Research In Schizophrenia | Phase 4 | BBB |
Opc-34712 Humanis Saglık Anonim Sirketi | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →